Agreement Between Physician Evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis

Area of Science:

• Rheumatology
• Clinical Trials
• Systemic Sclerosis Research

Background:

• Diffuse cutaneous systemic sclerosis (SSc) is a complex and highly variable autoimmune disease.
• The Composite Response Index in diffuse cutaneous SSc (CRISS) is a provisional 1-year outcome measure for clinical trials.
• Further validation of the CRISS is necessary to confirm its reliability in assessing treatment efficacy.

Purpose of the Study:

• To validate the Composite Response Index in diffuse cutaneous SSc (CRISS) by comparing its improvement criteria with expert physician evaluations.
• To assess the agreement between the CRISS cutoff score and physician-determined outcomes in patients with diffuse cutaneous SSc.

Main Methods:

• Patient profiles of 100 diffuse cutaneous SSc patients (50 improved, 50 non-improved by CRISS) with <5 years disease duration were analyzed.
• Three expert physicians independently evaluated each patient's disease status at baseline and 1 year.
• Kappa statistics were used to calculate agreement between physician majority opinion and the CRISS cutoff of 0.6.

Main Results:

• Substantial agreement was found between the CRISS and physician majority opinion (κ = 0.76).
• Individual physician agreement with the CRISS was also substantial (κ = 0.70).
• While all CRISS non-improvers were deemed non-improved by physicians, 12 CRISS improvers were classified as non-improved by physicians.

Conclusions:

• The CRISS cutoff of 0.6 demonstrates substantial agreement with physician assessments for evaluating improvement in diffuse cutaneous SSc.
• The CRISS is a validated outcome measure for clinical trials in diffuse cutaneous SSc.
• Physician assessments identified fewer improved patients compared to the CRISS, suggesting a potential difference in sensitivity.